218 related articles for article (PubMed ID: 25012765)
1. Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial.
Kianimehr G; Fatehi F; Hashempoor S; Khodaei-Ardakani MR; Rezaei F; Nazari A; Kashani L; Akhondzadeh S
Daru; 2014 Jul; 22(1):55. PubMed ID: 25012765
[TBL] [Abstract][Full Text] [Related]
2. A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia.
Khodaie-Ardakani MR; Khosravi M; Zarinfard R; Nejati S; Mohsenian A; Tabrizi M; Akhondzadeh S
Acta Med Iran; 2015; 53(6):337-45. PubMed ID: 26069170
[TBL] [Abstract][Full Text] [Related]
3. Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial.
Usall J; Huerta-Ramos E; Labad J; Cobo J; Núñez C; Creus M; Parés GG; Cuadras D; Franco J; Miquel E; Reyes JC; Roca M;
Schizophr Bull; 2016 Mar; 42(2):309-17. PubMed ID: 26591005
[TBL] [Abstract][Full Text] [Related]
4. Specificity proteins 1 and 4 in peripheral blood mononuclear cells in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial.
Vila È; Huerta-Ramos E; Núñez C; Usall J; Ramos B
Eur Arch Psychiatry Clin Neurosci; 2019 Dec; 269(8):941-948. PubMed ID: 30167782
[TBL] [Abstract][Full Text] [Related]
5. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
Kulkarni J; Gavrilidis E; Gwini SM; Worsley R; Grigg J; Warren A; Gurvich C; Gilbert H; Berk M; Davis SR
JAMA Psychiatry; 2016 Sep; 73(9):947-54. PubMed ID: 27438995
[TBL] [Abstract][Full Text] [Related]
6. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
[TBL] [Abstract][Full Text] [Related]
7. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial.
Huerta-Ramos E; Labad J; Cobo J; Núñez C; Creus M; García-Parés G; Cuadras D; Franco J; Miquel E; Reyes JC; Marcó-García S; ; Usall J
Eur Arch Psychiatry Clin Neurosci; 2020 Sep; 270(6):729-737. PubMed ID: 31728631
[TBL] [Abstract][Full Text] [Related]
8. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.
Usall J; Huerta-Ramos E; Iniesta R; Cobo J; Araya S; Roca M; Serrano-Blanco A; Teba F; Ochoa S
J Clin Psychiatry; 2011 Nov; 72(11):1552-7. PubMed ID: 21903021
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive raloxifene for postmenopausal women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.
Zhu XM; Zheng W; Li XH; Cai DB; Yang XH; Ungvari GS; Ng CH; Wang XP; Kulkarni J; Grigg J; Ning YP; Xiang YT
Schizophr Res; 2018 Jul; 197():288-293. PubMed ID: 29395611
[TBL] [Abstract][Full Text] [Related]
11. Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial.
Moazen-Zadeh E; Bayanati S; Ziafat K; Rezaei F; Mesgarpour B; Akhondzadeh S
J Psychopharmacol; 2020 May; 34(5):506-513. PubMed ID: 32122230
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.
Farokhnia M; Sabzabadi M; Pourmahmoud H; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Akhondzadeh S
Psychopharmacology (Berl); 2014 Feb; 231(3):533-42. PubMed ID: 24013610
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic study of the effects of raloxifene on negative symptoms of postmenopausal women with schizophrenia: A double-blind, randomized, placebo-controlled trial.
Labad J; Martorell L; Huerta-Ramos E; Cobo J; Vilella E; Rubio-Abadal E; Garcia-Pares G; Creus M; Núñez C; Ortega L; Miquel E; ; Usall J
Eur Neuropsychopharmacol; 2016 Oct; 26(10):1683-9. PubMed ID: 27546373
[TBL] [Abstract][Full Text] [Related]
14. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia.
Kulkarni J; Gurvich C; Lee SJ; Gilbert H; Gavrilidis E; de Castella A; Berk M; Dodd S; Fitzgerald PB; Davis SR
Psychoneuroendocrinology; 2010 Sep; 35(8):1142-7. PubMed ID: 20171784
[TBL] [Abstract][Full Text] [Related]
15. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
Ghajar A; Gholamian F; Tabatabei-Motlagh M; Afarideh M; Rezaei F; Ghazizadeh-Hashemi M; Akhondzadeh S
Hum Psychopharmacol; 2018 Jul; 33(4):e2662. PubMed ID: 29901250
[TBL] [Abstract][Full Text] [Related]
16. L-Theanine adjunct to risperidone in the treatment of chronic schizophrenia inpatients: a randomized, double-blind, placebo-controlled clinical trial.
Shamabadi A; Fattollahzadeh-Noor S; Fallahpour B; A Basti F; Khodaei Ardakani MR; Akhondzadeh S
Psychopharmacology (Berl); 2023 Dec; 240(12):2631-2640. PubMed ID: 37697164
[TBL] [Abstract][Full Text] [Related]
17. L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial.
Zeinoddini A; Ahadi M; Farokhnia M; Rezaei F; Tabrizi M; Akhondzadeh S
J Psychiatr Res; 2014 Dec; 59():125-31. PubMed ID: 25227564
[TBL] [Abstract][Full Text] [Related]
18. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial.
Akhondzadeh S; Ghayyoumi R; Rezaei F; Salehi B; Modabbernia AH; Maroufi A; Esfandiari GR; Naderi M; Ghebleh F; Tabrizi M; Rezazadeh SA
Psychopharmacology (Berl); 2011 Feb; 213(4):809-15. PubMed ID: 20949350
[TBL] [Abstract][Full Text] [Related]
19. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
Khodaie-Ardakani MR; Mirshafiee O; Farokhnia M; Tajdini M; Hosseini SM; Modabbernia A; Rezaei F; Salehi B; Yekehtaz H; Ashrafi M; Tabrizi M; Akhondzadeh S
Psychiatry Res; 2014 Mar; 215(3):540-6. PubMed ID: 24480077
[TBL] [Abstract][Full Text] [Related]
20. Raloxifene trial in postmenopausal woman with treatment-resistant schizophrenia.
Tharoor H; Goyal A
Arch Womens Ment Health; 2015 Oct; 18(5):741-2. PubMed ID: 26189131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
